Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people who take Wegovy do lose a meaningful amount of weight. In the pivotal STEP 1 trial, adults using semaglutide 2.4mg alongside lifestyle changes lost an average of around 15% of their body weight over 68 weeks — roughly 15 kg for someone starting at 100 kg. That figure comes from a large, rigorous trial, not a marketing sheet. How much you personally lose depends on several factors that are worth understanding before you start, because Wegovy is a prescription-only medicine and a clinician needs to assess whether it is appropriate for you and at what dose. This page walks through the decision you are actually making, not just whether Wegovy works in general, but what shapes results for individuals and what to expect along the way. Learn more about semaglutide and the biology behind how it reduces appetite.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP 1 trial results are striking, and they are genuine. Published in the New England Journal of Medicine, the study found roughly 15% average weight loss over 68 weeks among adults who took semaglutide 2.4mg alongside a reduced-calorie diet and increased activity. About one in three participants lost 20% or more. Those are population averages, though, and averages conceal a wide spread.
The spread exists because weight is shaped by biology. Starting body weight, metabolic rate, how your gut absorbs the medicine, how far you have already titrated your dose, sleep, stress, any underlying conditions, all of these influence your individual trajectory. There is a persistent misconception that GLP-1 medicines simply melt fat regardless of what else you do. They do not. Wegovy reduces appetite and slows the rate at which your stomach empties, which makes eating less far more manageable. The calorie deficit still has to happen; the medicine makes it easier to sustain.
One thing that does not vary: the evidence is built on lifestyle change alongside the injection, not instead of it. If you want to understand how to get the most from Wegovy in practice, what you eat and how active you are genuinely moves the needle on your personal outcome.
The titration schedule is gradual by design. Wegovy starts at 0.25mg for four weeks, then increases in stages, typically reaching 2.4mg at around month five. The early doses are primarily about tolerability (letting your system adjust) so the period when will i lose weight on semaglutide becomes a real question for many people is usually after the first dose increase, around weeks four to eight.
Most people notice appetite changes before the scales shift. Fullness arrives earlier at meals, the urge to snack fades, and portion sizes naturally contract. Weight loss that shows up on the scales tends to lag slightly behind those subjective changes. A closer look at the early timeline can help set realistic expectations for the first month or two, which is the phase when people most often worry that nothing is happening.
Progress also accelerates as the dose increases toward maintenance. If your prescriber has approved a step up, the effect on appetite typically deepens within a week or two of the new dose. Tracking your weight weekly rather than daily tends to reduce unnecessary anxiety, because day-to-day fluctuations in water retention can obscure the underlying trend. Some people also notice unexpected changes in mood or desire at this stage, and if you are curious about whether Wegovy affects libido and what the evidence says, it is a more common question than many people expect.
NICE guidance on semaglutide (Wegovy) sets a clear checkpoint: if someone loses less than 5% of their body weight after six months on their maintenance dose, the clinical recommendation is to reconsider whether continuing treatment is appropriate. That is not a punishment, it is a recognition that the medicine does not work the same way for everyone, and that continuing indefinitely without meaningful benefit is not in the patient's interest.
That threshold matters when you are deciding whether to start, because it frames Wegovy as a clinically monitored treatment rather than a supplement you take indefinitely regardless of effect. Every repeat prescription at nume is reviewed by a GPhC-registered prescriber before it is approved. Your progress is part of that review. The question of whether semaglutide will specifically help you is one your prescriber explores at consultation, looking at your health history, your current weight, and any conditions that might affect your response.
For context on what legitimate, regulated private treatment involves and what to expect in terms of cost, the guide to accessing Wegovy safely in the UK covers the supply chain and what a genuine pharmacy process looks like. You can also read about how the nume team is structured and the clinical oversight behind every prescription. When you are ready to speak to a prescriber about your own circumstances, starting with a free consultation is the straightforward next step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.